Tekla Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tekla Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.37M	Hold	65,490	–	–	0.09%	108
2023 Q1	$2.43M	Hold	65,490	–	–	0.09%	115
2022 Q4	$2.97M	Sell	65,490 -56,900	-46%	-$3.68M	0.11%	101
2022 Q3	$8.55M	Buy	122,390 +38,606	+46%	+$2.86M	0.35%	59
2022 Q2	$5.62M	Hold	83,784	–	–	0.22%	83
2022 Q1	$6.89M	Hold	83,784	–	–	0.24%	80
2021 Q4	$12.3M	Hold	83,784	–	–	0.4%	59
2021 Q3	$14.8M	Hold	83,784	–	–	0.48%	55
2021 Q2	$13.5M	Hold	83,784	–	–	0.44%	58
2021 Q1	$14.4M	Hold	83,784	–	–	0.49%	54
2020 Q4	$18.4M	Buy	83,784 +5,000	+6%	+$1.08M	0.65%	42
2020 Q3	$13.1M	Hold	78,784	–	–	0.49%	51
2020 Q2	$8.99M	Hold	78,784	–	–	0.34%	61
2020 Q1	$6.06M	Buy	78,784 +7,911	+11%	+$709K	0.27%	71
2019 Q4	$9.13M	Sell	70,873 -8,814	-11%	-$850K	0.35%	68
2019 Q3	$6.21M	Buy	79,687 +66,097	+486%	+$6.2M	0.27%	69
2019 Q2	$1.4M	Hold	13,590	–	–	0.06%	150
2019 Q1	$996K	Hold	13,590	–	–	0.04%	161
2018 Q4	$576K	Hold	13,590	–	–	0.02%	184
2018 Q3	$640K	Buy	+13,590	New	+$757K	0.02%	195

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tekla Capital Management's MRTX Position: Q2 2023 in Review

Tekla Capital Management held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q2 2023 at 65,490 shares worth $2.37M. The position accounts for 0.09% of the portfolio, ranked #108.

Tekla Capital Management first reported a position in MRTX in Q3 2018 and has held it in 20 quarters since. The position peaked at $18.4M in Q4 2020. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Tekla Capital Management held 65,490 shares of Mirati Therapeutics, Inc. Common Stock worth $2.37M as of Q2 2023.
Tekla Capital Management left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q2 2023.
Mirati Therapeutics, Inc. Common Stock made up 0.09% of Tekla Capital Management's portfolio in Q2 2023, its #108 holding.
Tekla Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 20 quarters since.
Tekla Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $18.4M in Q4 2020.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.